[TimAlerts] $VSTM “Dr. Matthew Davids gave an oral presentation of new clinical data from the ongoing Phase Ib/II study evaluating duvelisib in combination with FCR (chemo-immunotherapy) in younger, fit CLL patients,” said Diep Le, MD, PhD, Chief Medical Officer of Verastem Oncology. “The combination regimen achieved an overall response rate (ORR) of 94%, including 26% of patients experiencing a complete response or complete response with incomplete blood count recovery (CR/CRi), and 68% achieving a partial

[TimAlerts] $VSTM up on offering at higher price than expected ($6.00 per share). I think this is a good candidate for a buy https://finance.yahoo.com/news/verastem-oncology-announces-43-0-200300103.html Verastem Oncology Announces $43.0 Million Offering of Common Stock

[TimAlerts] $VSTM put an alert for if it breaks back about 3.45, then I'll be interested. If it breaks 3.70, it'll break the downward LT chart pattern

[TimAlerts] $VSTM FDA accepts NDA filing, up P/M with good volume. Known to run for 2 days or so

[TimAlerts] Premarket +10% - APOP, $VSTM, NVCM , $TRPX took a week off to move and had work but this morning is looking juicy (wasntme)